ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1010

Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies

Stephanie Finzel1, Veronika Lang2, Arnd Kleyer1, Juergen Rech3, Bernhard Manger1, Elizabeth Araujo1, Axel J. Hueber4, Ulrike Harre5 and Georg Schett1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, 3Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, anti-citrullinated protein/peptide antibodies (ACPA), Bone density, computed tomography (CT) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly induce bone loss by stimulating osteoclast differentiation (Harre et al, J Clin Invest 2012;122:1791). As ACPA precede the clinical onset of RA we hypothesized that ACPA positive healthy individuals may shows skeletal changes.

Methods: performed a comparative micro computed tomography analysis of the bone microstructure in the metacarpophalangeal joints (MCPJ) of ACPA positive and -negative healthy individuals without signs of arthritis.

Results:

ACPA positive (N= 10) and -negative (N= 10) healthy individuals were not different in age (48.2 ± 4.1 vs. 51.4 ± 3.8 years, p = 0.57) and gender (each 8 females and 2 males). Bone minaral density was significantly reduced in ACPA-positive individuals (mean  ± SEM: 280 ± 11 mg/ccm) as compared to controls (327 ± 6 mg/ccm). Bone loss was based on cortical bone changes with significant (p = 0.044) reduction in cortical thickness in the ACPA-positive group (mean  ± SEM: 0.22 ± 0.03 mm) as compared to controls (0.32 ± 0.03 mm).

Conclusion:

Structural bone damage starts before the clinical onset of arthritis in subjects with ACPA. These findings revise the concept of bone damage as an exclusive consequence of synovitis in ACPA positive individuals.


Disclosure:

S. Finzel,
None;

V. Lang,
None;

A. Kleyer,
None;

J. Rech,
None;

B. Manger,
None;

E. Araujo,
None;

A. J. Hueber,
None;

U. Harre,
None;

G. Schett,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bone-loss-before-clinical-onset-of-rheumatoid-arthritis-o-subjects-with-anti-citrullinated-protein-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology